Therapeutic area intelligence for Endothelin Receptor Antagonist with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Natco Pharma →

Assets

Bosentan →

Recent signals(1)

RegulatoryJune 27, 2026

FDA Accepts Supplement Application for Bosentan by Natco Pharma

The FDA has accepted a supplemental application for Bosentan submitted by Natco Pharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.